Highlights IMV Corporation

Equities

7760

JP3100760002

Delayed Japan Exchange Other stock markets 07:00:00 02/07/2024 BST			5-day change	1st Jan Change
806 ^JPY	+0.50%		-0.74%	+54.70%

04-09	Tranche Update on IMV Corporation's Equity Buyback Plan announced on November 21, 2023.	CI
03-25	BioVaxys Technology Plans Private Placement; Down 5.9%	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tranche Update on IMV Corporation's Equity Buyback Plan announced on November 21, 2023.	04-09	CI
BioVaxys Technology Plans Private Placement; Down 5.9%	03-25	MT
Biovaxys Completes The Acquisition Of All Intellectual Property And Clinical Stage Assets Of The Former IMV Inc.	02-21	MT
BioVaxys Acquires Entire Technology Portfolio Of The Former IMV Inc.	02-12	MT
Tranche Update on IMV Corporation's Equity Buyback Plan announced on November 21, 2023.	01-15	CI
IMV Corporation announces an Equity Buyback for 400,000 shares, representing 2.45% for ¥250 million.	11-21	CI
IMV Corporation authorizes a Buyback Plan.	11-20	CI
IMV Corporation Reports Earnings Results for the Full Year Ended September 30, 2023	11-10	CI
EKF Diagnostics hires CFO from Trellus Health, latter names successor	12/09/23	AN
Imv Corporation Provides Dividend Guidance for the Fiscal Year Ending September 30, 2023	09/06/23	CI
Imv Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2023	09/06/23	CI
IMV Corporation Reports Earnings Results for the Half Year Ended March 31, 2023	12/05/23	CI
IMV Receives Delisting Notice From Nasdaq Over Bankruptcy Proceedings in Canada	09/05/23	MT
IMV Inc. Brief: Says Received NASDAQ Delisting Notice	08/05/23	MT
IMV Inc. Brief: Says Received Nasdaq Notification Regarding Minimum Bid Price Deficiency	31/03/23	MT
IMV Inc. Brief: Hall Adds Co engaged Stonegate to explore strategic alternatives, "So that MVP-S can realize its full clinical potential"	16/03/23	MT
IMV Inc. Brief: Andrew Hall, Chief Executive Officer, Said" "The market headwinds limiting available capital are, however, very real"	16/03/23	MT
IMV Inc. Brief: Net loss and comprehensive loss of US$38.0 million ($4.55 per share) for Year ended December 31, 2022, Vs net loss and comprehensive loss of $36.6 ($4.93 per share) for Year ended December 31, 2021	16/03/23	MT
IMV Inc. Brief: As of December 31, 2022, Co had cash and cash equivalents of US$21.2 million and working capital of $18.2 million, compared to $38.6 million and $37.1 million, respectively on December 31, 2021	16/03/23	MT
IMV Inc. Brief: Says Has engaged Stonegate Healthcare Partners, L.L.C to explore strategic alternatives following a review of its business	16/03/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights IMV Corporation

Equities

7760

JP3100760002

Highlights

Filters